Author Interviews, JAMA, Pulmonary Disease / 10.12.2020
Idiopathic Pulmonary Fibrosis: Co-trimoxazole Therapy Did Not Prevent Disease Progression
MedicalResearch.com Interview with:
Andrew M. Wilson, MD
Clinical Senior Lecturer in Respiratory Health
University of East Anglia
Norwich and Honorary Consultant Physician in Respiratory Medicine
Norfolk and Norwich University
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Idiopathic pulmonary fibrosis has a poor prognosis and limited treatment options. Clinical trial evidence suggested a survival benefit for people taking co-trimoxazole and microbiological data suggested that infection was implicated in prognosis. However this large multicentre study did not show that co-trimoxazole had an beneficial effect in terms of time to all-cause mortality, hospitalisation or lung transplant in people with moderate and severe idiopathic pulmonary fibrosis
(more…)